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Summary.-Thirteen gliomas from 55 neurosurgical specimens, derived from 25
adults and 30 children, have been successfully grown as subcutaneous xenografts in
immune-deprived or nude mice. Only 2 of the 30 paediatric specimens implanted
(6.7%) a medulloblastoma and an astrocytoma Grade III, have grown compared
with 11 of the 25 adult specimens (44%) which were mostly astrocytomas Grade III.
Tumour growth usually occurred several months after implantation, and karyotypic
analysis confirmed their human origin in all cases. The histopathology of xeno-
grafted tumours correlated with the original surgical material, both after initial
implantation and when tumours had been passaged several times. Observations on
tumour growth in various types of immune-deprived mice indicated that, within
certain limits, the immunological competence of the host mouse did not relate to take
rates of primary implants, but could affect the take rate of passaged tumours.
The five-year survival of patients with
astrocytoma Grades III or IV is < 5 o,
despite improvements in radiotherapeutic
procedures with or without antecedent
surgery. Thus, interest in the use of
adjuvant chemotherapy in such cases has
intensified. Variousnitrosourea compounds
such as BCNU, CCNU and MeCCNU have
some effect in the treatment of recurrent
gliomas, but their value as adjuvants
in primary treatment remains to be
proved. A combination of CCNU and
vincristine has been used in the treatment
of some medulloblastomas and high grade
ependymomas, and recently international
controlled trials of such regimes in Europe
and the USA have been established
(Bloom, 1976; A. E. Evans, personal
communication).
Other drugs, such as dianhydrogalac-
titol, procarbazine, VM26, hexamethyl-
melamine and DTIC have also been
tried sporadically, but firm indications for
their use are still lacking.
In an attempt to provide an experi-
mental model for the use of cytotoxic and
chemical radiosensitising agents in the
treatment of human gliomas, we have
tried to ascertain the optimum conditions
for the growth of such tumours in experi-
mental animals. We hope that the methods
derived will complement studies on murine
ependymomas (Ausman et al., 1970) and
rat astrocytomas (Benda et al., 1971;
Rosenblum et al., 1975). The preliminary
testing of multiple drug and combined
modality regimes against human brain
tumours grown in mice may suggest more
effective treatments against the com-
parable tumours in patients.
MATERIALS AND METHODS
Primary human tumours.-Specimens of
human gliomas wereobtainedduringoperation
at the neurosurgical units of Atkinson
Morley's Hospital and the Hospital for
Sick Children, Great Ormond Street. They
were kept in sterile TC199 medium contain-
ing penicillin, 200 U/ml, and streptomycin,
100 ,ug/ml (Wellcome Reagents, Beckenham,
Kent) at 4°C, prior to their implantation
into mice, usually within 5 h of their removal
from the patient.
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6-week-old mice of the Chester Beatty CBA
inbred strain, of either sex, were T-cell-
deprived according to a technique published
elsewhere (Cobb and Mitchley, 1974) based on
an earlier method of Miller (1963). Briefly,
mice were thymectomised 4-6 weeks before
exposure to a potentially lethal dose of whole
body irradiation (900 rad from a 220 kV
X-ray machine). After irradiation, the mice
were given an injection of 5 x 106 syngeneic
marrow cells from normal sex-matched
donors. In one experiment, described later,
this procedure was varied in age at thy-
mectomy and number of marrow cells
injected.
(ii) Nude mice.-Adult, congenitally athy-
mic colony-bred nude mice were also used.
They were kept in sterile Makralon cages with
air-filter covers, bedded on irradiated saw-
dust, fed irradiated diet and were given
mildy acidified water (pH 2.8-3.0) ad libitum.
The cages were cleaned and the food and
water replenished in sterile isolators.
Implants of primary human cerebral
glioma.-The number of mice used and the
number of tumour implants per animal
varied according to the amount of tissue
available. Optimally, 4 pieces of viable-
looking tumour, each 10-20mm3, were
implanted subcutaneously into the flanks of
each of 5 mice previously anaesthetized with
ether.
At least one piece of tissue was fixed in
Bouin's solution for subsequent histological
determination of the type of tumour im-
planted. All animals were examined regularly
for the presence of subcutaneous nodules at
the implant sites. Growth of each nodule was
quantified by measuring with calipers along
3 axes, and the tumour mass expressed as a
volume by substituting in the equation,
Volume = (7Td3)/6, where d3 represents the
product of the 3 axes. Mice were kept for at
least 6 months unless killed owing to ill-health
or the presence of a tumour greater than
2 cm3. All animals were subject to post-
mortem examination. Remnants of tumour
implants, and any organs showing gross
pathological changes, were fixed in Bouin's
solution for histological examination. Tum-
ours at implant sites were usually excised
when 1-2 cm3, and used for (a) histological
examination as a check on tumour type and
grade, (b) transplantation to another group
of mice, and (c) storage at -196°C in liquid
N2 for future reference.
Storage of tumour tissue.-Tumour pieces
4 mm in diameter were placed for 10 min
in a solution of sterile freshly prepared 10%
dimethyl sulphoxide in TC199 before being
cooled at 1°C/min to -196°C. Plastic vials
containing frozen tumours were stored in a
liquid nitrogen bank. Tumours removed from
the bank were thawed as quickly as possible
and washed x 3 in TC199 at room tempera-
ture before implantation.
Karyotyping.-Karyotypic analysis was
carried out on all tumours which grew well
enough to be heterotransplanted. In some
instances, it was possible to compare the
karyotypes of these tumours with those of
the original specimen prior to its implantation
into mice.
Prior to karyotypic analysis, tumour
tissue was finely minced with scissors and a
crude cell suspension prepared by aspiration
through a 21-gauge hypodermic needle. Both
direct (3 h culture in colcemid) and indirect
(pre-culturing for 24 h) cultures in TC199
containing 10% human AB serum were
performed. Only chromosome preparations
with good morphology and spread were
selected for close examination.
RESULTS
Human glioma implants
Tumour specimens from each of 55
patients (25 adults and 30 children) have
been implanted (1-4 pieces per animal)
into the subcutaneous flank tissue of
groups of 1 to 5 immune-deprived or nude
mice. The gliomas from 13 patients have
grown successfully (Table I). Ten of
these tumours were astrocytomas of
Grades III and IV malignancy (9 adults,
1 child); 2 were medulloblastomas (1
adult and 1 child) and 1 an oligodendro-
glioma from an adult.
Although at the time of writing some
tumours are in their first passage, others
have grown and been passaged to further
groups of mice. Four astrocytomas Grade
III have been passaged for up to 5
generations before no further growth
occurred. The one astrocytoma Grade
IV is now in its 10th passage, whilst one
medulloblastoma was passaged 3 times
before no further growth occurred.265 HUMAN GLIOMA XENOGRAFTS
TABLE I.-Takes of tumours in various host mice
(a) In Standard Immune-deprived Mice
Intracranial
tumour type
Astrocytoma
Grade I
Astrocytoma
Grade II
Astrocytoma
Grade III
Astrocytoma
Grade IV
Medulloblastoma
Ependymoma
Oligodendroglioma
Ganglioglioma
Reticulum cell
sarcoma
Cerebral neuro-
blastoma
Pineal gland
germinoma
Totals
Take rate of
No. of Number of Takes of individual
specimens Patientst mice implants specimens specimens (%)
1 9 Ic. 5
4* 9 2c J0
63 2c 10
15*tt 9 4a 18
cT 9a 37
9? 1c 4
6§ Ic 5
1 9 la 6
10* 6 la 2
9? 2c 6
6 7c 33
7 6 la 5
9 4c 19
6§ 2c 10
4 9 4a 14
1 6 lc 3
1 9 la 5
1 6 lc 5
1 d Ic 4
209 21a 201
46 266 25c
10
30
15
41
87
8
20
6
4
14
66
5
41
15
36
12
5
20
4
439
1
5
1
1
1
1
1
11
5
33; 25; 40; 40; 30
62
83
75
20
12
5%-83%
(b) In Nude Mice
Astrocytoma
Grade II
Astrocytoma
Grade III
Medulloblastoma
Meningioma
Totals
1 s lc 4
3 9 la 2
6s 2a 6
2 6s 2c 5
1§ 3 Ic 5
19 3a
7 66S 4c 22
(c) In Modified Immune-deprived MIice
Astrocytoma
Grade III
Medulloblastoma
Ependymoma
Meningioma
Totals
7 9 la 5
63 4a 17
6 2c 8
1 d Ic 5
1 9 Ic 6
1 d lc 5
10 29 5a 46 86 Sc
t Sex, number and adult (a) or child (c).
* 1 astrocytoma Grade II, 3 astrocytomas Grade III, 2 medulloblastomas also implanted in nude mice
(see Table lb).
tt 1 astrocytoma Grade III also implanted in modified immune-deprived mice (Table lc).
§ 1 meningioma also implanted into modified immune-deprived mice (Table 1c).
16
8
22
20
10
1
1
5
12 5
76 2 5%; 12.5%
20
19
28
20
6
10
103
2
2
75; 20
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Growth characteristics of human gliomas in
mice
Initial growth of the primary implants
of the astrocytomas was delayed for
about 5 months, before tumours became
palpable. This reduced to about 2 months
in later passages. Growth of medullo-
blastoma specimens from 2 patients occur-
red after 7 and 4 months, respectively.
The first of these was passaged 3 times
with a delay before perceptible growth,
on each occasion, of 4 months. The second
tumour has not, so far, been successfully
transplanted after its first passage. All
tumours, irrespective of type, generally
had doubling times of about 2 months,
although there was a considerable range
of growth rate (3 weeks to 5 months)
around this figure for tumours from the
same or from different patients.
The transplanted tumours were gener-
ally found as encapsulated masses of
jelly-like tissue, similar in appearance to
the primary tumours in their natural state.
Metastatic tumour spread has, so far, not
been observed. Histological examination
of tumours which have grown and of
subsequently passaged tumours has shown
close similarity in cellular morphology
and differentiation to the primary clinical
tumour. The karyotypic analysis in all
cases investigated confirmed the human
origin of the transplanted tumours. Only
very rarely has a murine karyotype been
seen in what we suppose is an infiltrating
or stromal cell. There were no consistent
karyotypic abnormalities in 15 tumours
examined from the original surgical speci-
men, which is in agreement with other
published observations on brain tumours
(Lubs and Salmon, 1965; Hansteen, 1967).
Growth of an astrocytoma Grade IV in
immune-deprived mice
Particular attention was paid to the
specimen of an astrocytoma Grade IV
which had a high initial primary take-rate
of 83% (5/6 implants in 6 immune-
deprived mice) reducing to a mean of 70%
in subsequent passages. Growth curves for
transplants of this tumour have been
uniform since the 4th passage. There was
a mean delay in perceptible growth of
7 weeks, and the mean tumour-doubling
time was also 7 weeks. Paraffin sections of
tumour tissue stained with haematoxylin
and eosin and examined at each passage
showed a close similarity with each other,
and with sections of the original surgical
specimen. Features common to both
surgicalspecimen(Fig. la)andtransplanted
tissue (Figs. lb-d) were representative of
a high-grade astrocytoma, and included
pleomorphic cells in a disorganized
pattern, a few being multi-nucleated,
frequent mitoses (mean = 3/high power
field) pseudo-pallisading of tumour cells
around areas of necrosis, and many
thin-walled blood vessels showing endo-
thelial proliferation. Electron microscopy
of passaged tumour revealed fibrils (Fig.
2a) which are characteristic of glial cells
(Raimondi, 1966). However, by the 9th
passage these fibrils were no longer evi-
dent in the majority of the cells, and the
predominant tumour-cell type had an
irregular-shaped nucleus with a prominent
nucleolus, with expanded rough endo-
plasmic reticulum. This type of cell (Fig.
2b) closely resembles that observed in in
vitro cultures of astrocytoma by Guner
et al. (1977). No virus-like particles have
been observed in late-stage-passaged
astrocytoma tissue by electron micro-
scopical examination.
The karyotype of the tumour was
checked at the 2nd, 5th and 7th passage
and its human origin confirmed each time.
The modal number of chromosomes was
47, with the extra chromosome being a
metacentric, probably of Group B, which
was present in all cells examined. A few
polyploid cells were also seen.
Effects of the immunological competence of
host mice on growth of human gliomas
For several serial transfers of the astro-
cytoma Grade IV, 4 pieces of tumour
were implanted into each recipient. The
mean take rate was 70%. We compared
the observed frequency of animals havingHUMAN GLIOMA XENOGRAFTS
(b)
I.
FIG. 1.-(a) Diagnostic slide ofsurgical specimen ofastrocytoma GradeIV,showingfibrillaryastrocytes
in a disorganised pattern with an example of pseudo-pallisading surrounding an area of necrosis.
(b) The same tumour after 1st passage in immune-deprived mice, (c) the 6th passage with(d)the 10th
passage. Sections stained with H & E; magnification x 415.
(d)
(,-IL)
(c)
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FIG. 2.-(a) Electron micrograph of transplanted astrocytoma (3rd passage) showing a typical astro-
cyte with lysosomes (L), mitochondria (M), irregular-shaped nucleus (N) and normal endoplasmic-
reticulum (ER). Magnification x 10,000. Inset is detail from same cell demonstrating cytoplasmic
fibrils (F). Magnification x 100,000. (b) Electron micrograph ofsame tumour (9th passage) showing
loss of fibrils and the presence of expanded rough endoplasmic reticulum (ER). Magnification
x 10,000.
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TABLE II.-Analysis ofhomogeneity of immune deprivation
No tumours/mouse
Specimen
Astrocytoma Grade IV
7th passage, takes = 8/20
Astrocytoma Grade III
1st passage, takes = 16/20
Astrocytoma Grade III
Primary implants, takes =
Observed frequency
Expected frequency
Observed frequency
Expected frequency
Observed frequency
6/20 Expected frequency
0 1 2 3 4
0 3 1 1 0
0-6 1-8 1-7 0-7 0-1
0 0 2 0 3
0-01 0-1 0-8 2-0 2-0
2 1 1 1 0
1-2 2-1 1-3 0 4 0-04
Expected tumour frequencies were obtained by binomial distribution analysis. Comparisons
of observed and expected frequencies were made by Kolmiogorov-Smirnoff analysis. P >
0-05 in all cases.
1, 2, 3, 4 or no tumours with that expected
on the basis that it was a random event.
There was no significantdifferencebetween
the observed and expected frequencies of
tumour growth in 5 animals each im-
planted with 4 pieces of tumour in the 7th
passage. Similarly, tumours arose in 5
mice implanted with an astrocytoma
Grade III in the first passage with the
expected frequency, as did tumours arising
from a primary implant of astrocytoma
Grade III. These results (Table II)
indicate that our immune-deprived mice
were probably homogeneous in relation
to their capacity to support tumour
growth, and that there was no interaction
between tumours.
In a further series of experiments, the
take rate of the astrocytoma Grade IV
was determined in the congenitally athy-
mic nu/nu (nude) mouse. These mice have
been shown capable of supporting the
growth of many different types of tumour
(Rygaard and Povlsen, 1969; Giovanella
et al., 1974; Shimosato et al., 1976). All
tumours (1-4 pieces per mouse in its
seventh passage) implanted into 7 nude
mice grew. The growth curves oftumour in
this type of animal, subjected to regres-
sion analyses, indicated that the mean
tumour doubling time of 7-6 weeks was
not significantly different (P > 0.1) from
the 7.4 weeks of the same tumour growing
in immune-deprived mice (Fig. 3).
As a result of these studies, primary
tumours have been implanted, where pos-
sible, to groups of both nude and immune-
deprived mice. Of 7 tumours implanted
E E:
EZ
E
a,
0
Weeks Following Implantation
FIG. 3. Growth of astrocytoma Grade IV
(7th passage) in nude and immune-deprived
mice. Eatch of 6 nude or immune-deprived
mice were implanted with 1 piece oftumour
in the subcutaneous space of the right flank
and tumour volumes measured weekly.
(2 medul]loblastomas, 1 astrocytoma
Grade II, 3 astrocytomas Grade III and
1 meningioma) only 2 have grown (Table
Ib). One, a medulloblastoma, was im-
planted in 2 nude (4 tumour pieces/mouse)
and 5 immune-deprived mice (2 tumour
pieces/mouse). One transplant grew in the
nude mice (12-5% take rate) and one in
each of 2 immune-deprived mice (20o
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take rate). The second tumour that
has grown in this experiment was an
astrocytoma Grade III. One specimen
has grown in 1 of 5 nude mice (4
tumour pieces/mouse) (5%o take rate),
whilst no tumours have grown so far in the
corresponding immune-deprived mice.
Thus, in this small number of specimens,
primary human glioma tissue has not
been shown to grow preferentially in nude
mice compared with immune-deprived
mice.
An alternative type of host has also
been examined. During the preparation
of immune-deprived mice, S. I. Detre
(in preparation) in this laboratory has
examined the effects ofvarying the time of
thymectomy and the number of marrow
cells given post-irradiation in an attempt
to further deprive these animals. Groups
of 5 mice were thymectomized by Detre
at age 4 or 8 weeks and were reconstituted
with either 5 x 106 or 105 marrow cells
post-irradiation. A further group of mice
was thymectomized by us at age 5 weeks
and reconstituted with 5 x 106 marrow
cells. All animals were given implants of
the astrocytoma Grade IV, 8th passage,
one piece s.c. in each flank. Thymectomy
at 8 weeks followed by whole-body
irradiation and i.v. injection of 105 marrow
cells resulted in the highest tumour take
rate of 100%o (Table III). No difference
TABLE III. Effect ofage at thymectorny
and number of marrow cells on take
rate of astrocytoma Grade I
'
Age at thy- No. of marrow
mectomy cells for reconsti-
(weeks) tution ( x 105) Take rate (0)
4 50 40
4 1 70
8 50 75
8 1 100
5 50 60
There were 5 mice in each group; all mice were
age- and sex-matched cage-mates. They were sorted
into groups after irradiation by applying random
numbers. The marrow inoculum was in a final
volume of 0 -4 ml.
was found in tumour growth rate, nor in
the interval between implantation and
TABLE IV.-Comparison of take rates
of astrocytoma Grade IV in various
types of immuzne-deficient mice.
Tumour
Standlard immune-deprivedl
mice
Modified immune-deprived
mice
Nude mice
Astrocytoma IV
69.2% (36/52)
100% (10/10)
1()0% (24/24)
Numbers in brackets are the number of tumours
growing from the number of implants. Tumour was
in its 7th an(d 8th passage.
perceptible tumour growth in the various
types of immune-deprived mice. A comp-
arison of the take rates of passaged astro-
cytoma Grade IV in nude, standard and
modified immune-deprived mice is shown
in Table IV.
From a total of 10 tumours, 7 primary
specimens of astrocytoma Grade III have
been implanted to these modified (thy-
mectomy at 8 weeks, 105 marrow cells
post-irradiation) immune-deprived mice
(Table Ic). One specimen implanted solely
to 2 such animals, each given 2 pieces of
tumour, has grown, with a 75%o take rate.
There was a delay in perceptible growth
after implantation of 3 months. This
tumour has been successfully transplanted
to standard mice (thymectomy at 5 weeks,
5 x 106 marrow cells post-irradiation)
(4 tumour pieces/mouse) where its take
rate was 350o (tumour in first passage).
Another astrocytoma Grade III has grown
in both types of mice following primary
implantation. A group of 5 standard and
5 modified immune-deprived mice were
implanted with tumour, one piece in the
subcutaneous flank tissue of each animal.
The tumour take rate in the two groups
was 4000 and 20%, respectively. However,
the delay in perceptible tumour growth in
the standard immune-deprived mice was
three months, whilst that in the modified
immune-deprived mice was 6 months.
Tumour from the former mice has been
successfully passaged to further large
groups (more than 30 mice per group)
of standard immune-deprived mice where
its take rate has increased to a mean of
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850%. Thus, the initial low take rate has
not been reflected in subsequent passages.
One medulloblastoma, one ependymoma
and one meningioma have also been im-
planted to the modified immune-deprived
mice and have failed to grow. The menin-
gioma also did not grow in a group of 5
nude mice. From the small number of
primary implantsin bothtypes ofimmune-
deprived mice, there does not appear to
be any preferential take of tumour in the
more immune-deprived animals.
DISCUSSION
Ourobservationsillustrate thefeasibility
of growing a proportion of human brain
tumours in immune-deficient mice. At
best, 5000 of Grade III astrocytomas can
be successfully implanted in such animals.
The reason why the other 5000 failed to
grow are obscure. It could be due to re-
sidual immunological responsiveness in the
mice, in which case nude or further-
deprived animals might, in the long run,
prove more receptive hosts: limited ex-
perience with such animals in the present
study, however, does not support this
view. Alternatively, it has been suggested
(Cobb and Mitchley, 1974) that there is an
imbalance between cell proliferation and
death.
It is worth noting that 11/25 tumours,
mostly high-grade astrocytomas from
adults, grew in immune-deprived mice,
compared with only 2/30 tumours from
children.Thismaysimplyreflectthenormal
low incidence of high-grade astrocytomas
in childhood. However, the failure of
medulloblastomas from children to grow
is surprising, in view of their known
aggressive character in patients. Our
preliminary attempts to grow these
tumours in the brains of deprived mice
were unsuccessful, giving no support to
the notion that medulloblastomas may
need a specific brain milieu for growth in
a xenogeneic host.
The question of why transplants of
highly malignant tumours often take
several months to show perceptible growth
is not easily answered. The fairly constant
doubling times which were found, once
growthhadcommenced, cannotbeextrapo-
lated back without some knowledge ofcell-
loss factors. It could be that relatively few
tumour cells in the transplants are actually
involved in subsequent growth. This is
compatible with a doubling time of 2
months and a delay before palpability of
4 months or more. Further studies are
required to resolve this issue.
Most, but not all, of the tumours which
grew initially were transplantable into
further hosts, which is the usual experi-
ence of those who have been involved
with xenograft studies (Shimosato et al.,
1976; Berenbaum et al., 1974). The growth
rates and histopathological picture of
the initial specimens were maintained in
subsequent transplants, although future
take rates improved in most instances.
Again, no reason can be given for this
effect, except to suppose that in some way
the tumours had becomeconditionedtothe
physiological milieu of the mouse.
The eventual loss of fibrils in the
majority of cells in the astrocytoma
Grade IV, revealed by electron micro-
scopy in later passages, may reflect a loss
of differentiation, not detected by light
microscopy. With time and increasing
passage number in mice, the tumours will
probably deviate more and more from
their initial appearance andgrowthcharac-
teristics and may thereby become less suit-
ableasmodelsforchemotherapeuticstudies.
The advantage of serially transplanting
tumours, as opposed to primary implanta-
tion, in the most immunologically ineffec-
tive mice was revealed in the present
study. The analysis of tumour takes per
animal suggests that the residual immune
response operating in standard immune-
deprived mice may well prevent the
growth of one tumour but be unable to
prevent that of another in the same
animals. That this is not due simply to
total exhaustion of the immunological
apparatus is suggested by the absence of
interaction between transplanted tumours
in the same animal.
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The establishment and growth ofhuman
brain tumours in immunologically reduced
mice is a feasible proposition. Although
the growth of 2 human glioblastomas and
1 mengingioma in mice has been described
previously from these laboratories and
elsewhere (Cobb and Mitchley, 1974;
Rana et at., 1977) the present study deals
with a larger series of the type of gliomas
that can be expected to grow. Our pre-
liminary observations suggest that such
tumours in immune-reduced mice respond
to chemotherapeutic agents (CCNU,
BCNU) which have been successful in man.
It is, as yet, unclear whether the experi-
mental system we have described will be
suitable for screening new agents of pos-
sible clinical therapeutic value, and for
studies of the metabolism of human
tumours.
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